Compare Canadian National Railway Co. (CNI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canadian National Railway Co. vs Merck & Co., Inc. — how do they compare? Canadian National Railway Co. trades at $124.02 (market cap $75.02B), while Merck & Co., Inc. trades at $123.7 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 4× Canadian National Railway Co.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| CNI | MRK | |
|---|---|---|
Market Cap | $75.02B | $298.31B |
Sector | Industrials | Health |
52-Week High | $125.31 | $129.52 |
52-Week Low | $90.91 | $77.60 |
Enterprise Value | $90.48B | $341.72B |
Dividend Yield | 2.07% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canadian National Railway (CNI) trades at $125.31, up 0.73% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with 27.23% net income margin and 21.85% ROE, though valuation multiples appear elevated with P/E of 23.44. Recent record grain and propane shipments highlight operational strength, while Q2 2026 earnings due July 24 will be critical for near-term direction.
CNI presents a mixed outlook with strong operational execution offset by premium valuation. The 35% upside to consensus target of $143.25 offers potential, but debt-to-asset ratio rising to 36.61% and competitive pressures warrant caution. Dividend sustainability appears solid with recent $0.92 payout, making it attractive for income investors seeking railroad exposure.
Merck (MRK) trades at $123.52, down 0.41% on the day, amid a bullish technical signal and strong institutional interest. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Valuation ratios include a P/E of 34.02 and P/S of 4.58, while cash flow from operations remains healthy at $16.47B in 2025.
The outlook for MRK is positive, driven by earnings beats, a dominant oncology portfolio, and analyst consensus favoring buys. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06 in 2025, and competitive pressures in the pharmaceutical sector. The stock offers potential upside to the consensus price target of $137.30, but investors should monitor execution risks from recent acquisitions and macroeconomic factors affecting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
